65 related articles for article (PubMed ID: 23513884)
1. [Pancreatic carcinoma].
Okamoto T; Onda S
Nihon Rinsho; 2012 Nov; 70 Suppl 8():463-7. PubMed ID: 23513884
[No Abstract] [Full Text] [Related]
2. Erlotinib in pancreatic cancer patients: do we need more information from the NCIC CTG trial?
Mandalà M; Moro C; Labianca R; Ferretti G
J Clin Oncol; 2007 Sep; 25(27):4320-1; author reply 4321-2. PubMed ID: 17878488
[No Abstract] [Full Text] [Related]
3. Combining epidermal growth factor receptor inhibitors and radiation therapy in pancreatic cancer: small step or giant leap?
Chang BW; Saif MW
JOP; 2009 May; 10(3):231-6. PubMed ID: 19454812
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer.
Welch SA; Moore MJ
Future Oncol; 2007 Jun; 3(3):247-54. PubMed ID: 17547518
[TBL] [Abstract][Full Text] [Related]
5. Perspectives in central nervous system malignancies.
Stummer W
IDrugs; 2006 Jun; 9(6):412-4. PubMed ID: 16752310
[No Abstract] [Full Text] [Related]
6. [Report from a small registry-permetrexed, tarceva and yondelis].
Pochop L; Hejduk K
Klin Onkol; 2013; 26(1):53-4. PubMed ID: 23607142
[No Abstract] [Full Text] [Related]
7. Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer?
Laurent-Puig P; Taieb J
Curr Opin Oncol; 2008 Jul; 20(4):454-8. PubMed ID: 18525343
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib as an effective therapy for advanced hepatocellular carcinoma with lung metastasis?
Chen WC; Chen W; Tseng GC; Lai HC; Shih CM; Hsia TC
Liver Int; 2010 Nov; 30(10):1548-9. PubMed ID: 20345702
[No Abstract] [Full Text] [Related]
9. [Neuroendocrine tumors: the age of targeted therapies].
Capdevila J; Argilés G; Mulet-Margalef N; Tabernero J
Endocrinol Nutr; 2012; 59(7):438-51. PubMed ID: 22565119
[TBL] [Abstract][Full Text] [Related]
10. Allelic ratio of KRAS mutations in pancreatic cancer.
Lennerz JK; Stenzinger A
Oncologist; 2015 Apr; 20(4):e8-9. PubMed ID: 25777349
[No Abstract] [Full Text] [Related]
11. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
Wolin EM
Cancer Lett; 2013 Jul; 335(1):1-8. PubMed ID: 23419523
[TBL] [Abstract][Full Text] [Related]
12. Temsirolimus for advanced renal cell carcinoma.
Figlin RA
Clin Adv Hematol Oncol; 2007 Nov; 5(11):893. PubMed ID: 18185488
[No Abstract] [Full Text] [Related]
13. [Current status and perspectives of individualized therapy for non-small cell lung cancer based on molecular targeting].
Shi YK
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):398-400. PubMed ID: 22883466
[No Abstract] [Full Text] [Related]
14. Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors.
Bukowski RM
Clin Genitourin Cancer; 2007 Sep; 5(6):359-61. PubMed ID: 17956708
[No Abstract] [Full Text] [Related]
15. Everolimus 10 mg and pancreatic neuroendocrine tumours: many adverse effects and uncertain benefit.
Prescrire Int; 2012 Oct; 21(131):234. PubMed ID: 23185844
[TBL] [Abstract][Full Text] [Related]
16. Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus.
Piha-Paul SA; Cohen PR; Kurzrock R
J Clin Oncol; 2011 Sep; 29(26):e727-30. PubMed ID: 21844496
[No Abstract] [Full Text] [Related]
17. Molecule of the month. Temsirolimus.
Drug News Perspect; 2007; 20(6):406. PubMed ID: 17925894
[No Abstract] [Full Text] [Related]
18. Temsirolimus (Torisel) for advanced renal cell carcinoma.
Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
[No Abstract] [Full Text] [Related]
19. Targeting mTOR in mantle cell lymphoma: current and future directions.
Smith SM
Best Pract Res Clin Haematol; 2012 Jun; 25(2):175-83. PubMed ID: 22687453
[TBL] [Abstract][Full Text] [Related]
20. [Progress of molecularly targeted therapy for breast cancer].
Ito Y
Rinsho Ketsueki; 2012 Apr; 53(4):426-32. PubMed ID: 22687976
[No Abstract] [Full Text] [Related]
[Next] [New Search]
